Selecta Biosciences, Inc. Free Cash Flow Margin

Free Cash Flow Margin of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was 205.7% (a -126.74% decrease from previous year)
  • Annual Free Cash Flow Margin for 2019 was -769.21% (a -88.41% decrease from previous year)
  • Annual Free Cash Flow Margin for 2018 was -6638.54% (a -73.96% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending December 30, 2020 was 146.75% (a -42.04% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin increased by Infinity% year-over-year
Trailing Free Cash Flow Margin for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
146.75% 253.21% 0.0% 0.0%
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Selecta Biosciences, Inc.

Most recent Free Cash Flow Marginof SELB including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 205.7%
2019 -769.21%
2018 -6638.54%
2017 -25490.82%
2016 -250.74%
2015 -393.05%
2014 -424.77%

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.